Oral semaglutide offers a paradigm shift for cardiovascular risk management with tablet convenience | Research

The takeaway

Oral semaglutide provides equivalent cardiovascular risk reduction to injectable formulations in T2DM, offering a paradigm shift from injectable to oral GLP-1 therapy for comprehensive cardiometabolic management.

Oral = injectable CV protection
Oral semaglutide matches injectable forms for cardiovascular risk reduction while offering tablet convenience—potentially reaching millions more patients

What the researchers found

Oral semaglutide: equivalent CV benefits to injectable. MACE reduction demonstrated. Weight loss + glycemic control. Tablet convenience improves access/adherence. T2DM + CVD risk management.

Why it matters

Injectable administration is a major barrier to GLP-1 drug adoption. Oral semaglutide removes this barrier while maintaining cardiovascular protection—potentially reaching millions more patients.

How the study worked

Narrative review of oral semaglutide clinical evidence for cardiovascular risk management.

What this study cannot tell us

Narrative review. Oral semaglutide has dosing requirements (empty stomach, water restrictions) that may limit adherence. Head-to-head oral vs injectable CV outcome data is indirect.

How to read the evidence

Narrative review of clinical trial evidence. Strong for oral semaglutide efficacy.

When this study was published

Published in 2025.

The bigger picture

Moving from injectable to oral GLP-1 therapy is one of the most significant advances in cardiometabolic medicine, enabling population-level cardiovascular risk reduction through improved access.

Questions still open

Will oral semaglutide receive a formal cardiovascular indication?
Could next-generation oral GLP-1 drugs eliminate dosing restrictions?
Does improved adherence with oral form translate to better real-world outcomes?

Common questions

Can I take semaglutide as a pill instead of an injection?

Yes. Oral semaglutide (Rybelsus) provides equivalent cardiovascular and metabolic benefits to injectable semaglutide. You need to take it on an empty stomach with a small amount of water and wait 30 minutes before eating, but it eliminates the need for weekly injections.

Is the oral form as effective as injections for heart protection?

Based on current evidence, yes. Studies show oral and injectable semaglutide provide similar cardiovascular risk reduction. The choice between oral and injectable can be based on personal preference, lifestyle factors, and ability to manage the oral dosing requirements.

Read the original research

Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes.

European heart journal supplements : journal of the European Society of Cardiology, 27(Suppl 1), i1-i5

View on PubMed ↗Publisher’s paper ↗

Citation

Temporelli, Pier Luigi. (2025). Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes.. European heart journal supplements : journal of the European Society of Cardiology, 27(Suppl 1), i1-i5. https://doi.org/10.1093/eurheartjsupp/suae086